MetaCap

CNS Pharmaceuticals (CNSP) vs Theriva Biologics (TOVX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Theriva Biologics is the larger company by market cap ($5.5 million vs $5.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNSP-34.44%TOVX-48.72%
+2%-24%-51%
Oct 7, 20261 yearNov 20, 2026
CNSP-33.46%TOVX-44.70%
+2%-23%-48%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNSP versus TOVX key metrics
MetricCNSPTOVX
Share price$3.56$0.12
Market cap$5.25M$5.51M
1-day change-12.75%-6.25%
YTD return—-42.86%
1-year return—-45.45%
5-year return—-99.86%
P/E ratio (TTM)—0.10
EPS (TTM)$-11.80$1.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-15.85M$-23.74M
52-week high$10.54$0.49
52-week low$1.90$0.12
Distance from 52-week high-66.22%-75.51%
Analyst consensusnonenone
Avg. price target upside+180.90%+1983.33%
Average volume9.30K2.02M
Shares outstanding1.48M45.89M
Employees815
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About CNS Pharmaceuticals

CNSP stock →

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About Theriva Biologics

TOVX stock →

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

CNSP vs TOVX FAQ

Which is bigger, CNS Pharmaceuticals or Theriva Biologics?

Theriva Biologics (TOVX) is larger, with a market capitalization of $5.51M compared with $5.25M for CNS Pharmaceuticals (CNSP).

Are CNS Pharmaceuticals and Theriva Biologics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons